Clinical Trial Update: Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of oral dalfampridine extended-release (Fampridine-SR) in multiple sclerosis completed, with results posted on 2011-08-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fampridine-SR (fampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2011-08-04